Nickolai A. Barlev

Nickolai A. Barlev

Auto-generated profile, based on publicly available information

Nickolai A. Barlev

1] Department of Biochemistry, University of Leicester, Leicester LE1 9HN, UK [2] Molecular Pharmacology Laboratory, Saint-Petersburg Institute of Technology, Saint-Petersburg 190013, Russia [3] Gene Expression Laboratory, Institute of Cytology, Saint-Petersburg 194064, Russia

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2013 in Oncotarget
Verified
Journal Article
Open access
PDF file
DMDiana Marouco
Diana Marouco
AGAlexander V. Garabadgiu
Alexander V. Garabadgiu
GMGerry Melino
Gerry Melino
NBNikolai A. Barlev
Nikolai A. Barlev
Post-translational modifications provide a fine-tuned control of protein function(s) in the cell. The well-known tumour suppressor p53 is subject to many post-translational modifications, which alter its activity, localization and stability, thus ultimately modulating its response to various forms of genotoxic stress. In this review, we focus on the role of recently discovered lysine-specific modifications of p53, methylation and acetylation in particular, and their effects on p53 activity in damaged cells. We also discuss a possibility of mutual influence of covalent modifications in the p53 and histone proteins located in the vicinity of p53 binding sites in chromatin and propose important ramifications stemming from this hypothesis.

12 December 2013 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
LLL Lezina
L Lezina
NPN Purmessur
N Purmessur
AAA V Antonov
A V Antonov
TIT Ivanova
T Ivanova
EKE Karpova
E Karpova
NBN A Barlev
N A Barlev
The tumour suppressor p53 is a crucial regulator of cell cycle arrest and apoptosis by acting as a transcription factor to regulate a variety of genes. At least in part, this control is exerted by p53 via regulating expression of numerous microRNAs. We identified two abundantly expressed microRNAs, miR-16 and miR-26a, whose expression is regulated by p53 during the checkpoint arrest induced by the genotoxic drug, doxorubicin. Importantly, among the targets of these miRs are two critical checkpoint kinases, Chk1 and Wee1. The p53-dependent augmentation of miR-16 and miR-26a expression levels led to the cell cycle arrest of tumour cells in G1/S and increased apoptosis. Strikingly, the bioinformatics analysis of survival times for patients with breast and prostate cancers has revealed that co-expression of mir-16 and miR-26a correlated with a better survival outcome. Collectively, our data provide a novel mechanism whereby p53 represses Chk1 and Wee1 expression, at least partially, via upregulation of miR-16 and miR-26a and thus sensitizes tumour cells to genotoxic therapies.

15 August 2014 in Cell Death & Differentiation
Verified
Journal Article
Closed access
LLL Lezina
L Lezina
VAV Aksenova
V Aksenova
TIT Ivanova
T Ivanova
NPN Purmessur
N Purmessur
AAA V Antonov
A V Antonov
NBN A Barlev
N A Barlev

29 June 2013 in Oncotarget
Verified
Journal Article
Open access
PDF file
TMTatiana Moiseeva
Tatiana Moiseeva
ABAndrew R Bottrill
Andrew R Bottrill
GMGerry Melino
Gerry Melino
NBNickolai A. Barlev
Nickolai A. Barlev
Stability of proteins is largely controlled by post-translational covalent modifications. Among those, ubiquitylation plays a central role as it marks the proteins for proteasome-dependent degradation. Proteolytic activities of proteasomes are critical for execution of various cellular processes, including DNA damage signaling and repair. However, very little is known about the regulation of proteasomal activity in cells during genotoxic stress. Here we investigated post-translational modifications of the 20S proteasomal subunits upon DNA damage induced by doxorubicin. Using mass-spectrometry, we found novel sites of phosphorylation and ubiquitylation in multiple proteasome subunits upon doxorubicin treatment. Ectopic co-expression of proteasome subunits and tagged ubiquitin confirmed the presence of ubiquitylated forms of PSMA5, PSMA1, PSMA3 and PSMB5 in cells. Moreover, we demonstrated that ubiquitylation in vitro inhibited chymotrypsin-like and caspase-like activities of proteasomes. In vivo, doxorubicin increased the activity of proteasomes, paralleling with attenuation of the overall level of proteasome ubiquitylation. Collectively, our results suggest a novel mechanism whereby the proteolytic activities of proteasomes are dynamically regulated by ubiquitylation upon DNA damage.

11 January 2010 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
NBN A Barlev
N A Barlev
BSB S Sayan
B S Sayan
ECE Candi
E Candi
AOA L Okorokov
A L Okorokov

1 January 2015
Verified
Journal Article
Closed access
ADAlexandra Daks
Alexandra Daks
APA V Petukhov
A V Petukhov
OSO Yu Shuvalov
O Yu Shuvalov
EVE A Vasilieva
E A Vasilieva
GMG Melino
G Melino
OFO A Fedorova
O A Fedorova